Fukuoka University, Fukuoka, Japan.
Kojinkai Sapporo Skin Clinic, Sapporo, Japan.
J Dermatol. 2021 Jan;48(1):80-84. doi: 10.1111/1346-8138.15596. Epub 2020 Sep 10.
We evaluated the pharmacodynamic effects of apremilast in 69 patients who were included in biomarker subanalyses of a phase 2b study that demonstrated the long-term safety and efficacy of apremilast in Japanese adults with moderate to severe psoriasis. The association between cytokine levels and Psoriasis Area and Severity Index (PASI) improvement was evaluated using linear regression and Spearman's rank correlation coefficient analysis. At baseline, median plasma levels of interleukin (IL)-17A, IL-17F and IL-22 were elevated versus reference values for healthy individuals, whereas tumor necrosis factor-α levels were close to normal. With apremilast 30 mg b.i.d., there were significant associations between percentage change in PASI score and percentage change in IL-17A, IL-17F and IL-22 levels at week 16. Findings demonstrate that the efficacy of apremilast in psoriasis is associated with inhibition of key cytokines involved in the pathology of psoriasis.
我们评估了阿普米司特在 69 名患者中的药效学作用，这些患者纳入了一项 2b 期研究的生物标志物亚分析，该研究证明了阿普米司特在日本中重度银屑病成人患者中的长期安全性和疗效。采用线性回归和斯皮尔曼等级相关系数分析评估细胞因子水平与银屑病面积和严重程度指数（PASI）改善之间的相关性。基线时，与健康个体的参考值相比，白细胞介素（IL）-17A、IL-17F 和 IL-22 的血浆水平中位数升高，而肿瘤坏死因子-α水平接近正常。阿普米司特 30mg 每日两次治疗 16 周时，PASI 评分的变化百分比与 IL-17A、IL-17F 和 IL-22 水平的变化百分比之间存在显著相关性。这些发现表明，阿普米司特治疗银屑病的疗效与抑制银屑病发病机制中关键细胞因子有关。
